In contrast to CML, loss of Ikaros by deletion or mutation had been found in 80% of BCR-ABL-positive B-ALL cases and 29% of BCR-ABL-negative B-ALL high-risk patients [62, 63]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.